FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2330637982> ?p ?o ?g. }

• W2330637982 abstract "Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FLAkt is one of the most frequently activated protein serine/threonine kinases in human malignancies. As a central node of the PI3K-Akt-mTOR pathway, Akt plays a critical role in cancer initiation, progression and therapeutic resistance, representing an important and attractive cancer therapeutic target.Initial optimization of inhibitors, identified from a high-throughput screen against Akt1, led to potent pan-Akt inhibitors with poor selectivity over other kinases (e.g., the closely related protein kinase A, PKA). Guided by crystal structures of Akt1, Akt2, and PKA in complex with compounds, selectivity over PKA was improved dramatically. Subsequent optimization of pharmaceutical properties led to the discovery of GDC-0068, a potent, orally bioavailable, ATP-competitive pan-Akt inhibitor (enzymatic IC50 values of 5 to 30 nM for all 3 isoforms), that is highly selective over other kinases, including >100-fold selectivity over PKA.GDC-0068 blocks Akt signaling as demonstrated by dose-dependent inhibition of the phosphorylation of multiple downstream targets of Akt in human cancer cell lines. In the PTEN-deficient prostate cancer cell line LNCaP, GDC-0068 has a cellular IC50 value of 176 nM for the phosphorylation of the Akt substrate, PRAS40. In addition, GDC-0068 inhibits cell cycle progression and viability of cancer cell lines driven by Akt signaling, including those with defects in the tumor suppressor PTEN, oncogenic mutations in PIK3CA, and amplification of HER2. When dosed orally in xenograft cancer models, GDC-0068 induced pharmacodynamic knockdown of key Akt signaling outputs that correlated with drug exposure. Antitumor efficacy was observed in multiple xenograft tumor models, including those of human prostate, breast, ovarian, colon, glioma and melanoma origins. Tumor stasis or regression was achieved at well-tolerated oral doses in xenograft models predicted to be dependent on activated Akt signaling, such as the PTEN-deficient prostate cancer models LNCaP and PC3, and the PIK3CA H1047R mutant breast cancer model KPL-4. Consistent with the role of Akt in a survival pathway, GDC-0068 also demonstrated enhanced antitumor efficacy when combined with other therapeutic agents.Unlike allosteric inhibitor, whose potency was negatively affected by the activating mutations in Akt1, such as the E17K mutation found in human cancers, GDC-0068-like ATP-competitive inhibitors target activated Akt and exhibit enhanced potency on mutant Akt1. Novel discoveries on the mechanistic effects of ATP-competitive Akt inhibitors on the Akt protein will be discussed.In summary, GDC-0068 is a novel, highly selective ATP-competitive Akt inhibitor with compelling selectivity, efficacy, and oral pharmacokinetics that support its clinical development as an anti-cancer agent. The selective activity in cancer cells with activated Akt signaling allows for a rational strategy to potentially identify patients who will benefit in clinical trials. GDC-0068 is currently in phase I clinical trials in cancer patients.Special thanks to the Akt project teams at Array BioPharma and Genentech. Inc.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr DDT02-01. doi:10.1158/1538-7445.AM2011-DDT02-01" @default.
• W2330637982 created "2016-06-24" @default.
• W2330637982 creator A5020414889 @default.
• W2330637982 date "2011-04-15" @default.
• W2330637982 modified "2023-09-26" @default.
• W2330637982 title "Abstract DDT02-01: GDC-0068: A novel, selective, ATP-competitive inhibitor of Akt" @default.
• W2330637982 doi "https://doi.org/10.1158/1538-7445.am2011-ddt02-01" @default.
• W2330637982 hasPublicationYear "2011" @default.
• W2330637982 type Work @default.
• W2330637982 sameAs 2330637982 @default.
• W2330637982 citedByCount "1" @default.
• W2330637982 countsByYear W23306379822012 @default.
• W2330637982 crossrefType "proceedings-article" @default.
• W2330637982 hasAuthorship W2330637982A5020414889 @default.
• W2330637982 hasConcept C11960822 @default.
• W2330637982 hasConcept C121608353 @default.
• W2330637982 hasConcept C126322002 @default.
• W2330637982 hasConcept C154137905 @default.
• W2330637982 hasConcept C184235292 @default.
• W2330637982 hasConcept C185592680 @default.
• W2330637982 hasConcept C2777609662 @default.
• W2330637982 hasConcept C2779723316 @default.
• W2330637982 hasConcept C502942594 @default.
• W2330637982 hasConcept C55493867 @default.
• W2330637982 hasConcept C62112901 @default.
• W2330637982 hasConcept C62478195 @default.
• W2330637982 hasConcept C71924100 @default.
• W2330637982 hasConcept C75217442 @default.
• W2330637982 hasConcept C86554907 @default.
• W2330637982 hasConcept C88216763 @default.
• W2330637982 hasConcept C96232424 @default.
• W2330637982 hasConceptScore W2330637982C11960822 @default.
• W2330637982 hasConceptScore W2330637982C121608353 @default.
• W2330637982 hasConceptScore W2330637982C126322002 @default.
• W2330637982 hasConceptScore W2330637982C154137905 @default.
• W2330637982 hasConceptScore W2330637982C184235292 @default.
• W2330637982 hasConceptScore W2330637982C185592680 @default.
• W2330637982 hasConceptScore W2330637982C2777609662 @default.
• W2330637982 hasConceptScore W2330637982C2779723316 @default.
• W2330637982 hasConceptScore W2330637982C502942594 @default.
• W2330637982 hasConceptScore W2330637982C55493867 @default.
• W2330637982 hasConceptScore W2330637982C62112901 @default.
• W2330637982 hasConceptScore W2330637982C62478195 @default.
• W2330637982 hasConceptScore W2330637982C71924100 @default.
• W2330637982 hasConceptScore W2330637982C75217442 @default.
• W2330637982 hasConceptScore W2330637982C86554907 @default.
• W2330637982 hasConceptScore W2330637982C88216763 @default.
• W2330637982 hasConceptScore W2330637982C96232424 @default.
• W2330637982 hasLocation W23306379821 @default.
• W2330637982 hasOpenAccess W2330637982 @default.
• W2330637982 hasPrimaryLocation W23306379821 @default.
• W2330637982 hasRelatedWork W1973723861 @default.
• W2330637982 hasRelatedWork W1984942460 @default.
• W2330637982 hasRelatedWork W2000003016 @default.
• W2330637982 hasRelatedWork W2012002974 @default.
• W2330637982 hasRelatedWork W2014865890 @default.
• W2330637982 hasRelatedWork W2019077971 @default.
• W2330637982 hasRelatedWork W2019550192 @default.
• W2330637982 hasRelatedWork W2025554600 @default.
• W2330637982 hasRelatedWork W2046635534 @default.
• W2330637982 hasRelatedWork W2060275594 @default.
• W2330637982 hasRelatedWork W2065576728 @default.
• W2330637982 hasRelatedWork W2067956232 @default.
• W2330637982 hasRelatedWork W2128308297 @default.
• W2330637982 hasRelatedWork W2318529741 @default.
• W2330637982 hasRelatedWork W2329334073 @default.
• W2330637982 hasRelatedWork W2342852175 @default.
• W2330637982 hasRelatedWork W2550697711 @default.
• W2330637982 hasRelatedWork W2741843640 @default.
• W2330637982 hasRelatedWork W2790769039 @default.
• W2330637982 hasRelatedWork W2188799320 @default.
• W2330637982 isParatext "false" @default.
• W2330637982 isRetracted "false" @default.
• W2330637982 magId "2330637982" @default.
• W2330637982 workType "article" @default.